TNFRSF9 (TNF Receptor Superfamily Member 9)

These multi-layered analyses provide novel insights into epigenetic mechanisms underlying OL to OSCC progression and highlight candidate biomarkers with strong translational potential. By combining IML based methylation modeling with external and cross-omics validation, this study advances the development of reliable, interpretable biomarkers for precision oral cancer diagnostics and management.

Our study provides no evidence that sICs can predict LNM in PeCa, although four inhibitory sICs were significantly elevated in PeCa patients compared to cancer-free controls, suggesting systemic immunosuppression associated with tumor presence, consistent with findings in other malignancies. Studies with larger cohorts are warranted to clarify the prognostic significance of sICs in PeCa.

Theranostics offers an image-guided 'select-and-treat' paradigm for radionuclide therapy, yet target heterogeneity, dosimetry standardization, cost, and infrastructure remain barriers. Translation to routine care will require harmonized protocols, multicenter prospective validation, and demonstration of decision impact.

Although ex vivo expanded TILs are predominantly terminally differentiated, exhausted and transcriptionally highly distinct from the initial TILs, there is also a large progenitor exhausted CD8 T cell (Tpex) population and DN numbers increase. Future work to amplify subpopulations of TILs with memory cell phenotypes, such as the DN cells, will likely further improve this therapy.

P2, N=161, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

Future directions emphasize novel immune targets (MDSCs, SLAMF1), metabolic reprogramming, and microbiota modulation for precision therapies. Integrating multimodal approaches holds promise for halting NASH-to-HCC progression and improving outcomes.

The low response rates and hepatic safety signals observed do not support further clinical development of INBRX-105.

Furthermore, TNFRSF9 is suggested as an upstream determinant of osteomalacia, with the AMP to glutamate ratio identified as a potential biomarker. These results underscore the importance of utilizing these cytokines and metabolites in clinical practice for distinguishing between osteochondrosis and osteomalacia, as well as for exploring potential therapeutic interventions.

We fused the aptamer to short hairpin (sh) RNAs that are specific for Enhancer of zeste homolog 2 (EzH2) or neuropilin-1 (Nrp1), and demonstrated their uptake into CD137+ malignant cells and Tregs, and the subsequent downregulation or EzH2 and Nrp1. This study confirms CD137 as a target for tumor immunotherapy and introduces CD137 aptamer-shRNA chimeras as novel tools to be evaluated for their usefulness in cancer treatment.

B7-H3-specific CAR T cells exhibit potent antitumor activity against MM, with the next-generation construct (B7H3.CAR-NG) demonstrating superior cytotoxicity, persistence and cytokine production. These findings support the potential of B7H3.CAR-NG T cells as a promising therapeutic strategy for MM.

Except for soluble CD80, the detection of the other sICs by the bead-based assay was influenced by the matrix type. The evaluation of the best matrix for sICs should be considered before starting clinical studies.

Cryoablation is a promising nonsurgical treatment for early-stage BC. The procedure may induce immune activation by increasing HMGB1 and modulating T-cell populations. Tregs appear to decrease after cryoablation, suggesting immunomodulatory potential. Histopathology confirms effective tumor ablation in most treated patients. Cryoablation shows immunomodulatory effects and may provide a rationale for future combination with immunotherapy.